Tolerance Bio will increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance. Immune-mediated diseases represent a significant unmet medical challenge: cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergi
Total raised: $17.2M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.10.2024 | Seed | $17.2M | - |
Mentions in press and media 4
| Date | Title | Description |
| 20.10.2024 | Tolerance Bio: Pioneering the Future of Immune Health with $17.2 Million Seed Funding | In the world of biopharmaceuticals, innovation is the lifeblood. Tolerance Bio, a Philadelphia-based company, has just secured $17.2 million in seed funding. This financial boost is not just a number; it represents a beacon of hope for many... |
| 20.10.2024 | Tolerance Bio: $17.2 Million (Seed) Raised For Increasing Healthspan By Adjusting Function Of The Thymus | Tolerance Bio – a biopharmaceutical company pioneering a novel approach to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance – announced the closing of its ... |
| 15.10.2024 | Tolerance Bio Raises $17.2M in Seed Financing | Tolerance Bio, a Philadelphia, PA-based biopharmaceutical company providing a novel approach to increasing healthspan, raised $17.2M in Seed funding. The round was led by Columbus Venture Partners, with participation from Criteria Bio Ventu... |
| - | Tolerance Bio | “Tolerance Bio will increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance. Immune-mediated diseases represent a significant unmet medical challenge: cancer, autoimmunity, trans... |